Almirall, S.A. (ALM.MC)

8,39 +0,03 (+0,30%) Börsenschluss: 05:35PM CEST

Almirall, S.A.

Ronda General Mitre, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 1.904

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Carlos Gallardo Piqué	CEO, President, Member of Management Board & Chairman of the Board	50k	N/A	1972
Mr. Michael McClellan	CFO & Member of Management Board	N/A	N/A	1972
Mr. Eloi Crespo Cervera	Chief Industrial Operations Officer & Member of Management Board	N/A	N/A	N/A
Mr. Esteve Conesa Panicot	Chief People & Culture Officer and Member of Management Board	N/A	N/A	N/A
Dr. Volker Koscielny	Chief Medical Officer & Member of Management Board	N/A	N/A	N/A
Dr. Karl Ziegelbauer	Chief Scientific Officer & Member of Management Board	N/A	N/A	N/A
Mr. Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	N/A	N/A	N/A
Ms. Isabel Cristina Gomes	Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board	N/A	N/A	N/A
Ms. Mercedes Diz Lopez	Chief Marketing Officer & Member of Management Board	N/A	N/A	N/A
Mr. Pablo Divasson del Fraile	Senior Director of Investor Relations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2015 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Corporate Governance

Almirall, S.A.s ISS Governance QualityScore, Stand 1. April 2024, lautet 4. Die grundlegenden Scores sind Audit: 5, Vorstand: 4, Shareholderrechte: 3, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.